Jan Berghaus-Mueller

Langen, NI, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Regulatory challenges of personalized medicine in the real world: are the right patients being treated with CD19-targeting CAR T-cells?

Regulatory challenges of personalized medicine in the real world: are the right patients being treated with CD19-targeting CAR T-cells?

Journal: EMBO molecular medicine

Published: December 04, 2025

Balancing benefit and risk in early Alzheimer's disease: the European Medicines Agency (EMA) assessment of lecanemab and donanemab.

Balancing benefit and risk in early Alzheimer's disease: the European Medicines Agency (EMA) assessment of lecanemab and donanemab.

Journal: The Lancet regional health. Europe

Published: November 20, 2025

The European Medicines Agency review of sacituzumab govitecan for the treatment of triple-negative breast cancer.

The European Medicines Agency review of sacituzumab govitecan for the treatment of triple-negative breast cancer.

Journal: ESMO open

Published: March 02, 2022

Accelerated Development of COVID-19 Vaccines: Technology Platforms, Benefits, and Associated Risks.

Accelerated Development of COVID-19 Vaccines: Technology Platforms, Benefits, and Associated Risks.

Journal: Vaccines

Published: May 10, 2021

The EMA assessment of pembrolizumab as monotherapy for the first-line treatment of adult patients with metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer.

The EMA assessment of pembrolizumab as monotherapy for the first-line treatment of adult patients with metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer.

Journal: ESMO open

Published: March 10, 2021

EMA Review of Axicabtagene Ciloleucel (Yescarta) for the Treatment of Diffuse Large B-Cell Lymphoma.

EMA Review of Axicabtagene Ciloleucel (Yescarta) for the Treatment of Diffuse Large B-Cell Lymphoma.

Journal: The oncologist

Published: August 20, 2019

Extrapolation in the development of paediatric medicines: examples from approvals for biological treatments for paediatric chronic immune-mediated inflammatory diseases.

Extrapolation in the development of paediatric medicines: examples from approvals for biological treatments for paediatric chronic immune-mediated inflammatory diseases.

Journal: Archives of disease in childhood

Published: October 27, 2016

No association of IL-12p40 pro1.1 polymorphism with juvenile idiopathic arthritis.

No association of IL-12p40 pro1.1 polymorphism with juvenile idiopathic arthritis.

Journal: Pediatric rheumatology online journal

Published: December 03, 2015

The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.

The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.

Journal: The oncologist

Published: July 14, 2015

ICOS-LICOS interaction is critically involved in TGN1412-mediated T-cell activation.

ICOS-LICOS interaction is critically involved in TGN1412-mediated T-cell activation.

Journal: Blood

Published: May 12, 2012

Showing 1-10 of 10

Last Updated: 09/26/2026